VEGFA and neoplasm: However, many studies have shown that bevacizumab has a variety of side effects and strict indications for clinical use, thus limiting its wide clinical application.[12]In contrast, recombinant human endostatin (endostar), as an emerging anti-VEGF targeted tumor angiogenesis drug independently developed in China, has shown good application prospects in lung cancer, melanoma, nasopharyngeal cancer, and gastric cancer.[13]